Carboplatin doses depend on an estimate of kidney function. The 2025 international guideline (ADDIKD) recommends a newer estimate (BSA-adjusted CKD-EPI) over the old Cockcroft-Gault formula when kidney function cannot be measured directly, because it is more accurate. No study has yet shown that switching changes side effects or how well treatment works.
The recommendation. ADDIKD (2025) recommends BSA-adjusted eGFR CKD-EPI as an alternative to measured GFR in the Calvert formula, on clinical consensus with a strong recommendation, and calls the switch away from creatinine clearance a significant practice change, given the long reliance on creatinine clearance calculated by the Cockcroft-Gault equation. It notes that many prescribing software packages use creatinine clearance by default.
The evidence. In 2,471 patients at Cambridge, BSA-adjusted CKD-EPI was the most accurate published estimate against measured GFR, and Cockcroft-Gault gave a dose more than 20% off in 25.5% of patients against 18.6% (Janowitz 2017, abstract). These are dose-accuracy outcomes; ADDIKD's own outstanding questions add that cystatin C-based equations may be more accurate where eGFR is unreliable.
Shares the tags protocol-upgrade, upgrade:promising.
Shares the tags protocol-upgrade, upgrade:promising.
Shares the tags protocol-upgrade, upgrade:promising.
Shares the tags protocol-upgrade, upgrade:promising.
Shares the tags protocol-upgrade, upgrade:promising.
Shares the tags protocol-upgrade, upgrade:promising.
Shares the tags protocol-upgrade, upgrade:promising.
Shares the tags protocol-upgrade, upgrade:promising.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/